Endologix (ELGX +0.5%) receives premarket FDA approval for a broadened indication of it's 21Fr profile and smaller EVAR systems, including totally percutaneous endovascular aneurysm repair. The authorization is based on the successful outcome of it's first clinical trial, the PEVAR Trial.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs